BRPI0518250A2 - tratamentos anticÂncer - Google Patents

tratamentos anticÂncer

Info

Publication number
BRPI0518250A2
BRPI0518250A2 BRPI0518250-6A BRPI0518250A BRPI0518250A2 BR PI0518250 A2 BRPI0518250 A2 BR PI0518250A2 BR PI0518250 A BRPI0518250 A BR PI0518250A BR PI0518250 A2 BRPI0518250 A2 BR PI0518250A2
Authority
BR
Brazil
Prior art keywords
anticancer treatments
effective amount
therapeutically effective
anticancer
treatments
Prior art date
Application number
BRPI0518250-6A
Other languages
English (en)
Inventor
Lars-Axel Sternas
Ovid Trifan
De Velde Helgi Van
April Teitelbaum
Erard Gilles
Original Assignee
Pharma Mar Sa
Ortho Biotech Products L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518250(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa, Ortho Biotech Products L P filed Critical Pharma Mar Sa
Publication of BRPI0518250A2 publication Critical patent/BRPI0518250A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

TRATAMENTOS ANTICÂNCER. A presente invenção refere-se a um método de tratamento do corpo humano do câncer compreendendo administrar uma quantidade terapêutica eficaz de uma forma Lipossomal Peguilada da antraciclina Doxorrubicina ("PLD") em combinação com uma quantidade terapêutica eficaz de ET-743.
BRPI0518250-6A 2004-10-26 2005-10-26 tratamentos anticÂncer BRPI0518250A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (1)

Publication Number Publication Date
BRPI0518250A2 true BRPI0518250A2 (pt) 2008-11-11

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518250-6A BRPI0518250A2 (pt) 2004-10-26 2005-10-26 tratamentos anticÂncer

Country Status (26)

Country Link
US (1) US20090117176A1 (pt)
EP (1) EP1827500B1 (pt)
JP (2) JP4554684B2 (pt)
KR (1) KR101287918B1 (pt)
CN (1) CN101119750B (pt)
AT (1) ATE430586T1 (pt)
AU (1) AU2005298364B2 (pt)
BR (1) BRPI0518250A2 (pt)
CA (1) CA2582452C (pt)
CY (1) CY1110329T1 (pt)
DE (1) DE602005014380D1 (pt)
DK (1) DK1827500T3 (pt)
ES (1) ES2326825T3 (pt)
HR (1) HRP20090345T1 (pt)
IL (1) IL182352A (pt)
MX (1) MX2007004744A (pt)
NO (1) NO328958B1 (pt)
NZ (1) NZ554765A (pt)
PL (1) PL1827500T3 (pt)
PT (1) PT1827500E (pt)
RS (1) RS50822B (pt)
RU (1) RU2359700C2 (pt)
SI (1) SI1827500T1 (pt)
UA (1) UA87877C2 (pt)
WO (1) WO2006046080A2 (pt)
ZA (1) ZA200703396B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8444963B2 (en) 2006-06-19 2013-05-21 John Hopkins University Tumor specific delivery of therapeutic agents via liposomase
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
US7473681B2 (en) * 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
US6770653B2 (en) * 2001-03-06 2004-08-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
WO2002102311A2 (en) * 2001-06-15 2002-12-27 Cornerstone Pharmaceuticals Nanoparticles for treating targeted tissues and cells
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
US20040082856A1 (en) * 2002-07-16 2004-04-29 Alfred E. Mann Institute For Biomedical Engineering, University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
ZA200703396B (en) 2008-11-26
NZ554765A (en) 2010-01-29
MX2007004744A (es) 2007-10-23
PL1827500T3 (pl) 2009-09-30
CN101119750A (zh) 2008-02-06
EP1827500A2 (en) 2007-09-05
AU2005298364B2 (en) 2009-03-26
KR20070108135A (ko) 2007-11-08
RU2359700C2 (ru) 2009-06-27
CA2582452C (en) 2010-09-07
KR101287918B1 (ko) 2013-07-19
RU2007119545A (ru) 2008-12-10
JP4554684B2 (ja) 2010-09-29
HK1107766A1 (en) 2008-04-18
NO328958B1 (no) 2010-06-28
AU2005298364A1 (en) 2006-05-04
WO2006046080A8 (en) 2007-07-12
SI1827500T1 (sl) 2009-10-31
UA87877C2 (en) 2009-08-25
WO2006046080A2 (en) 2006-05-04
CN101119750B (zh) 2013-03-06
RS50822B (sr) 2010-08-31
WO2006046080A3 (en) 2006-10-19
PT1827500E (pt) 2009-08-05
IL182352A (en) 2016-07-31
IL182352A0 (en) 2007-07-24
CA2582452A1 (en) 2006-05-04
DE602005014380D1 (de) 2009-06-18
EP1827500B1 (en) 2009-05-06
DK1827500T3 (da) 2009-08-31
ES2326825T3 (es) 2009-10-20
JP2009292850A (ja) 2009-12-17
US20090117176A1 (en) 2009-05-07
NO20072543L (no) 2007-07-13
JP2008517991A (ja) 2008-05-29
ATE430586T1 (de) 2009-05-15
CY1110329T1 (el) 2015-01-14
HRP20090345T1 (en) 2009-08-31

Similar Documents

Publication Publication Date Title
NO20072543L (no) Anti-cancer-behandling
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
TW200724158A (en) Combination therapy in the treatment of cancer
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
WO2006117404A3 (de) Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
UA97144C2 (ru) Терапевтический пластырь для тригерных и акупунктурных точек и для меридианной терапии
BR0307979A (pt) Método e preparação farmacêutica para reduzir as toxicidades gastrointestinais induzidas por terapia citoablatica , e método para melhorar terapia citoablativa de câncer
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/704 (2006.01), A61K 31/4995 (2006.01), A61

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]